NCT04519710View on ClinicalTrials.gov

Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

September 15, 2021

Study Completion Date

October 15, 2023

Conditions
HBV
Interventions
BIOLOGICAL

o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B

to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B

Trial Locations (1)

75013

Valérie POURCHER, Paris

All Listed Sponsors
lead

Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

OTHER

NCT04519710 - Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies | Biotech Hunter | Biotech Hunter